New study puts schistosomiasis tests to the test in Near-Elimination zone
NCT ID NCT06808750
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study in Pemba, Tanzania, compared several diagnostic tests for Schistosoma haematobium, a parasitic worm that causes a debilitating disease. Researchers tested 801 schoolchildren using methods like urine filtration, AI microscopy, and molecular tests. The goal was to find the most accurate and practical tests for use in areas where the infection is becoming rare, to help guide elimination and surveillance efforts.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify the most reliable and practical tests for detecting schistosomiasis in areas where the disease is becoming rare, supporting elimination efforts.
- What could go wrong
- This is a completed diagnostic study, not a treatment trial. The results may not apply to other regions or populations, and the tests may still miss some infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
801 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Children from Pemba Island, United Republic of Tanzania, that attend one among the two pre-selected study primary schools in grade 3, 4, 5 or 6.
- Ages
-
6 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects fulfilling all of the following inclusion criteria are eligible for the initial screening: * Attendance of grade 3, 4, 5, or 6 in study school * Randomized to participate in initial screening * Written informed consent signed by the parents * Written assent signed by the participant if aged12-17 years old Subjects fulfilling all of the following inclusion criteria are eligible for the diagnostic study: * Attendance of grade 3, 4, 5, or 6 in study school * Randomized to participate in initial screening * Written informed consent signed by the parents * Written assent signed by the participant if aged12-17 years old * S. haematobium-positive urine filtration result in initial screening OR * S. haematobium-negative urine filtration result in initial screening, but randomized for participation in diagnostic study Exclusion Criteria: The presence of any one of the following exclusion criteria will lead to the exclusion of the subject in the initial screening: * Not attending any study school * Not attending grade 3, 4, 5 or 6 * Not randomized to participate in initial screening * No written informed consent signed by the parents submitted * No written assent signed by the participant if aged12-17 years old submitted * S. haematobium-negative urine filtration result in initial screening, and not randomized for participation in diagnostic performance study * Clinical significant sever disease The presence of any one of the following exclusion criteria will lead to the exclusion of the subject in the diagnostic study: * Not attending any study school * Not attending grade 3, 4, 5 or 6 * Not randomized to participate in initial screening * No written informed consent signed by the parents submitted * No written assent signed by the participant if aged12-17 years old submitted * S. haematobium-negative urine filtration result in initial screening, and not randomized for participation in diagnostic performance study * Clinical significant sever disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schistosoma haematobium are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Public Health Laboratory - Ivo de Carneri (PHL-IdC)
Chake Chake, Pemba Island, Tanzania
More trials for these conditions
Other studies related to the condition(s) this trial covers.